论文部分内容阅读
Objective: To identify and localize the synthesized targeting peptide A54 to liver cancer cell line BEL-7402 in vivo and in vitro for confirming the potential clinical application of peptide A54 in hepatocarcinoma targeting therapy. Methods: Phage A54 was confirmed by ELISA. Biotin and FAM labeled A54 peptides were identified and localized by means of immunohistochemistry and immunocytochemistry. Results: A54 peptide could target the liver-tumor tissue in vivo and adhere to several liver-tumor cells in vitro. FAM-labeled A54 peptides were localized on the membrane surface of liver-tumor cells. Conclusion: Synthesized A54 peptide obtained from in vivo phage display technology still kept special ability to adhere liver-tumor cell in vivo and in vitro. The A54 peptide could be a candidate carrier for hepatocarcinoma targeting therapy.